Skip to main content
. 2022 Jun 5;56(2):209–223. doi: 10.1111/apt.17046

FIGURE 3.

FIGURE 3

Potential effects and underlying mechanisms of PPAR agonists on liver vascular dysfunction. CAM, cell adhesion molecules; hep, hepatocyte; HM, hepatic macrophages; HSC, hepatic stellate cell; LSEC, liver sinusoidal endothelial cell.